
Nanobiotix stock gains on positive melanoma trial data
Investing.com -- Nanobiotix (NASDAQ:NBTX) shares rose 6.3% Monday following the release of final data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) with immune checkpoint inhi…